These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
311 related articles for article (PubMed ID: 25963435)
1. The synergistic effects of DNA-damaging drugs cisplatin and etoposide with a histone deacetylase inhibitor valproate in high-risk neuroblastoma cells. Groh T; Hrabeta J; Khalil MA; Doktorova H; Eckschlager T; Stiborova M Int J Oncol; 2015 Jul; 47(1):343-52. PubMed ID: 25963435 [TBL] [Abstract][Full Text] [Related]
2. Impact of histone deacetylase inhibitor valproic acid on the anticancer effect of etoposide on neuroblastoma cells. Groh T; Hrabeta J; Poljakova J; Eckschlager T; Stiborova M Neuro Endocrinol Lett; 2012; 33 Suppl 3():16-24. PubMed ID: 23353839 [TBL] [Abstract][Full Text] [Related]
3. The Histone Deacetylase Inhibitor Valproic Acid Exerts a Synergistic Cytotoxicity with the DNA-Damaging Drug Ellipticine in Neuroblastoma Cells. Cerna T; Hrabeta J; Eckschlager T; Frei E; Schmeiser HH; Arlt VM; Stiborová M Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29304031 [TBL] [Abstract][Full Text] [Related]
4. Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma. Poljakova J; Hrebackova J; Dvorakova M; Moserova M; Eckschlager T; Hrabeta J; Göttlicherova M; Kopejtkova B; Frei E; Kizek R; Stiborova M Neuro Endocrinol Lett; 2011; 32 Suppl 1():101-16. PubMed ID: 22167207 [TBL] [Abstract][Full Text] [Related]
5. Sodium valproate potentiates staurosporine-induced apoptosis in neuroblastoma cells via Akt/survivin independently of HDAC inhibition. Shah RD; Jagtap JC; Mruthyunjaya S; Shelke GV; Pujari R; Das G; Shastry P J Cell Biochem; 2013 Apr; 114(4):854-63. PubMed ID: 23097134 [TBL] [Abstract][Full Text] [Related]
6. Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells. Wang G; Edwards H; Caldwell JT; Buck SA; Qing WY; Taub JW; Ge Y; Wang Z PLoS One; 2013; 8(9):e76662. PubMed ID: 24098799 [TBL] [Abstract][Full Text] [Related]
7. Preclinical evidence for a beneficial impact of valproate on the response of small cell lung cancer to first-line chemotherapy. Hubaux R; Vandermeers F; Crisanti MC; Kapoor V; Burny A; Mascaux C; Albelda SM; Willems L Eur J Cancer; 2010 Jun; 46(9):1724-34. PubMed ID: 20451370 [TBL] [Abstract][Full Text] [Related]
8. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells. Rocchi P; Tonelli R; Camerin C; Purgato S; Fronza R; Bianucci F; Guerra F; Pession A; Ferreri AM Oncol Rep; 2005 Jun; 13(6):1139-44. PubMed ID: 15870934 [TBL] [Abstract][Full Text] [Related]
9. Valproic acid in the complex therapy of malignant tumors. Hrebackova J; Hrabeta J; Eckschlager T Curr Drug Targets; 2010 Mar; 11(3):361-79. PubMed ID: 20214599 [TBL] [Abstract][Full Text] [Related]
10. Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines. Das CM; Aguilera D; Vasquez H; Prasad P; Zhang M; Wolff JE; Gopalakrishnan V J Neurooncol; 2007 Nov; 85(2):159-70. PubMed ID: 17534580 [TBL] [Abstract][Full Text] [Related]
11. Effect of histone deacetylase inhibitors trichostatin A and valproic acid on etoposide-induced apoptosis in leukemia cells. Jasek E; Lis GJ; Jasinska M; Jurkowska H; Litwin JA Anticancer Res; 2012 Jul; 32(7):2791-9. PubMed ID: 22753739 [TBL] [Abstract][Full Text] [Related]
12. Sodium valproate, a histone deacetylase inhibitor, enhances the efficacy of vinorelbine-cisplatin-based chemoradiation in non-small cell lung cancer cells. Gavrilov V; Lavrenkov K; Ariad S; Shany S Anticancer Res; 2014 Nov; 34(11):6565-72. PubMed ID: 25368259 [TBL] [Abstract][Full Text] [Related]
13. Valproic Acid Increases CD133 Positive Cells that Show Low Sensitivity to Cytostatics in Neuroblastoma. Khalil MA; Hraběta J; Groh T; Procházka P; Doktorová H; Eckschlager T PLoS One; 2016; 11(9):e0162916. PubMed ID: 27627801 [TBL] [Abstract][Full Text] [Related]
14. Valproic acid shows a potent antitumor effect with alteration of DNA methylation in neuroblastoma. Gu S; Tian Y; Chlenski A; Salwen HR; Lu Z; Raj JU; Yang Q Anticancer Drugs; 2012 Nov; 23(10):1054-66. PubMed ID: 22863973 [TBL] [Abstract][Full Text] [Related]
15. Opposing effects of hMOF and SIRT1 on H4K16 acetylation and the sensitivity to the topoisomerase II inhibitor etoposide. Hajji N; Wallenborg K; Vlachos P; Füllgrabe J; Hermanson O; Joseph B Oncogene; 2010 Apr; 29(15):2192-204. PubMed ID: 20118981 [TBL] [Abstract][Full Text] [Related]
16. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines. Shirsath N; Rathos M; Chaudhari U; Sivaramakrishnan H; Joshi K Lung Cancer; 2013 Nov; 82(2):214-21. PubMed ID: 24051085 [TBL] [Abstract][Full Text] [Related]
17. [Inhibitory effect of VPA on multiple myeloma U266 cell proliferation and regulation of histone acetylation]. Zhu YF; Ye BG; Shen JZ; Lin CM; Lin FA; Shen SF; Xu CB Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Jun; 18(3):638-41. PubMed ID: 20561418 [TBL] [Abstract][Full Text] [Related]
18. The synergistic effects of valproic acid and fluvastatin on apoptosis induction in glioblastoma multiforme cell lines. Chang YL; Huang LC; Chen YC; Wang YW; Hueng DY; Huang SM Int J Biochem Cell Biol; 2017 Nov; 92():155-163. PubMed ID: 29017950 [TBL] [Abstract][Full Text] [Related]
20. Targeting histones for degradation in cancer cells as a novel strategy in cancer treatment. Yin Y; Zhu Q; Jiang T; Fan L; Qiu X Sci China Life Sci; 2019 Aug; 62(8):1078-1086. PubMed ID: 30465232 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]